InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.855
-0.055 (-2.88%)
At close: Jul 17, 2026, 4:00 PM EDT
1.904
+0.049 (2.66%)
After-hours: Jul 17, 2026, 5:18 PM EDT
InflaRx Employees
InflaRx had 65 employees as of December 31, 2025. The number of employees decreased by 9 or -12.16% compared to the previous year.
Employees
65
Change (1Y)
-9
Growth (1Y)
-12.16%
Revenue / Employee
$520
Profits / Employee
-$761,202
Market Cap
273.23M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 65 | -9 | -12.16% |
| Dec 31, 2024 | 74 | 12 | 18.97% |
| Dec 31, 2023 | 62 | 18 | 40.41% |
| Dec 31, 2022 | 44 | -12 | -20.75% |
| Dec 31, 2021 | 56 | 9 | 18.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Niagen Bioscience | 117 |
| SAB Biotherapeutics | 86 |
| Lineage Cell Therapeutics | 77 |
| ALX Oncology Holdings | 43 |
| Opus Genetics | 28 |
| Galectin Therapeutics | 9 |
| Greenwich LifeSciences | 8 |
IFRX News
- 17 days ago - InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos - GlobeNewsWire
- 2 months ago - InflaRx upgraded to Strong Buy from Outperform at Raymond James - TheFly
- 2 months ago - InflaRx price target raised to $8 from $6 at H.C. Wainwright - TheFly
- 2 months ago - InflaRx Transcript: Investor update - Transcripts
- 2 months ago - InflaRx Press release: Investor update - Filings
- 2 months ago - InflaRx Slides: Investor update - Filings
- 2 months ago - InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares - GlobeNewsWire
- 2 months ago - InflaRx to develop izicopan in AAV - TheFly